Zoetis Inc. (ZTS) Drops 2.35% After Earnings, EPS Tops Expectations, Beats Revenue

2026-02-13 · Stocks · QuoteReporter

Post Earning Analysis

Zoetis Inc. (ZTS) Drops 2.35% After Earnings, EPS Tops Expectations, Beats Revenue

Zoetis, Inc., founded in 1952 and headquartered in Parsippany, NJ, is a global leader in animal health. The company focuses on the development, manufacture, and commercialization of a broad range of products, including medicines, vaccines, diagnostic tools, biodevices, genetic tests, and precision animal health technologies. Zoetis serves both the United States and international markets, enhancing the health of animals worldwide.

Zoetis Inc. experienced a mixed response in the stock market following its Q4 2025 earnings release. Despite surpassing Wall Street’s earnings and revenue estimates for the fourth quarter, Zoetis’ stock faced challenges. Analysts expressed concerns about the company’s growth pathway, particularly noting a decline in key segments which could potentially impact future performance. This sentiment was reflected in the stock initially gaining after the earnings beat but then facing downward pressure due to growth concerns highlighted by analysts.

The company reported strong full-year growth for 2025, which was a positive highlight. However, the mixed analyst views and the highlighted challenges in key business segments suggest a cautious outlook for the stock. Investors and stakeholders are likely keen on understanding how Zoetis plans to address these challenges and drive growth in the coming periods. The stock’s future performance will likely be closely tied to the company’s ability to effectively manage and possibly rejuvenate these critical segments.

The current price of $125.64 represents a significant decline of 2.35% today, indicating recent bearish behavior. This price is notably below the 52-week and year-to-date highs of $174.46 and $174.86, respectively, suggesting a long-term downtrend with the price down by over 27% from these peaks. The proximity to the 52-week and YTD lows around $114.76, however, indicates that the price has not fully recovered from its lowest points this year, showing only a modest increase of about 9.48%.

The moving averages reveal mixed signals; the price is slightly above the 20-day and 50-day MAs by roughly 0.47% and 1.51%, respectively, suggesting some short-term bullish sentiment. However, the significant -11.53% difference from the 200-day MA underscores a prevailing long-term bearish trend.

The RSI at 50.71 indicates a neutral momentum, neither overbought nor oversold, while a MACD of 0.76 suggests a mild upward price momentum in the short term. This combination of indicators points to potential stabilization or slight recovery, but the overall market sentiment remains cautious given the long-term negative performance.

Zoetis Inc. (NYSE: ZTS), a global leader in animal health, announced its financial outcomes for the fourth quarter and the entire year of 2025. For Q4, the company reported a revenue increase of 3% year-over-year to $2.4 billion, with organic operational growth at 4%. Net income for the quarter rose to $603 million, translating to $1.37 per diluted share, marking a 4% and 6% increase respectively. Adjusted net income was $648 million, or $1.48 per adjusted diluted EPS, showing a growth of 3% and 6%.

For the full year, Zoetis achieved a revenue of $9.5 billion, a 2% increase from the previous year, with organic operational growth at 6%. Annual net income reached $2.7 billion, or $6.02 per diluted share, an 8% and 10% increase respectively. Adjusted net income stood at $2.8 billion, with an adjusted diluted EPS of $6.41, up 6% and 8%.

The U.S. segment saw a slight decline, while the International segment experienced robust growth, particularly in companion and livestock products. Looking ahead to 2026, Zoetis projects revenue between $9.825 billion and $10.025 billion, with EPS expected to range from $6.65 to $6.75 and adjusted EPS from $7.00 to $7.10.

The company highlighted its continued expansion, including approximately 185 geographic expansions and innovations, alongside significant advancements in diagnostics and regulatory approvals for new animal medications. No new share repurchase or dividend declarations were mentioned in the report.

Earnings Trend Table

The earnings per share (EPS) data over the observed quarters shows a generally positive trend in both estimated and reported EPS, with a few notable exceptions. Starting from November 2023, the EPS was accurately predicted at 1.36, showing minimal surprise. However, a significant deviation occurred in February 2024, where the reported EPS of 1.24 fell below the estimate by 6.01%, marking the only negative surprise in the period analyzed.

Post this dip, the company consistently surpassed EPS estimates, suggesting a recovery and improvement in performance or possibly conservative estimations by analysts. The largest positive surprise came in November 2024, with an 8.58% increase over the estimate. This peak was followed by a series of positive but smaller surprises, indicating a stabilization in surpassing expectations.

The trend suggests a robust financial performance in the latter quarters, particularly noteworthy in the consistent overachievement against estimates from May 2024 onwards. This pattern reflects positively on the company’s ability to exceed analyst expectations and possibly indicates improving operational efficiency or market conditions favoring the company’s financial growth.

Dividend Payments Table

The dividend data spanning from April 2024 to January 2026 indicates a clear trend of growth in dividend payouts. Initially, dividends were consistent at $0.432 per share from April 2024 through October 2024. This consistency suggests a period of stability in the company’s dividend policy.

Starting January 2025, there is a notable increase in dividends to $0.5 per share, which is maintained across four consecutive quarters, up to and including October 2025. This increment reflects a positive adjustment in the company’s dividend distribution, possibly indicative of improved financial performance or a strategic decision to return more capital to shareholders.

The most recent data point, January 2026, shows a further increase to $0.53 per share. This progression not only underscores a continued upward trajectory in dividend payments but also suggests confidence from the company’s management in its financial health and a commitment to providing shareholders with increasing returns on their investments. This trend of gradually increasing dividends could be attractive to potential and current investors looking for steady income growth.

The four most recent rating changes for the company in question reflect varied perspectives from different financial institutions, each adjusting their outlook based on their analysis and market conditions.

1. Piper Sandler (2026-01-22): This firm downgraded the company from “Overweight” to “Neutral” with a target price set at $135. This change indicates a shift in expectation, suggesting that the stock, while previously anticipated to outperform the market, is now expected to perform in line with the market average. The specific target price suggests a cautious outlook on the company’s growth prospects or potential market challenges.

2. BofA Securities (2025-12-15): Similar to Piper Sandler, BofA Securities adjusted their rating from “Buy” to “Neutral” and also set the target price at $135. This downgrade within a month of Piper Sandler’s adjustment underscores a potentially emerging consensus among analysts about moderated expectations for the company’s near-term performance.

3. Barclays (2025-12-09): Barclays initiated coverage with an “Equal Weight” rating and a target price of $136. This rating suggests that Barclays views the company as adequately valued at its current price with expected market performance. The slightly higher target price compared to Piper Sandler and BofA Securities might indicate a marginally more optimistic view but still aligns closely with the broader market sentiment.

4. KeyBanc Capital Markets (2025-11-21): KeyBanc Capital Markets initiated coverage with a “Sector Weight” rating, choosing not to set a specific target price. This rating implies a neutral stance, suggesting that the company is expected to perform in line with the average of its sector. The absence of a target price could indicate uncertainty or a wait-and-see approach based on upcoming developments or financial results.

Overall, these rating changes point towards a growing caution or realism about the company’s stock, with a slight convergence around the $135-$136 price range, indicating market analysts’ consensus on its current valuation.

The current price of the stock is $125.64, which is below the average target price indicated by recent analyst ratings. Specifically, Piper Sandler and BofA Securities both downgraded their ratings but maintained target prices of $135, while Barclays initiated coverage with a target price of $136. These target prices suggest a potential upside of approximately 7.4% to 8.2% from the current price.

The recent downgrades from “Overweight” and “Buy” to “Neutral” by Piper Sandler and BofA Securities respectively, alongside the neutral initiations by Barclays and KeyBanc Capital Markets (“Equal Weight” and “Sector Weight”), indicate a consensus view of moderate expectations regarding the stock’s future performance. This could reflect a view of fair valuation at current levels or potential concerns about future earnings growth or market conditions affecting the stock.

Unfortunately, specific EPS (Earnings Per Share) and dividend trends are not provided in the data. However, these financial metrics, along with the recent analyst ratings, would be crucial in assessing the overall financial health and investment appeal of the stock. Investors should consider these factors alongside market conditions and company-specific news when evaluating the potential for investment in this stock.

Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.